Follow The Filings

TNGX Tango Therapeutics Inc.

Health Care, filed as TANGO THERAPEUTICS INC (COM), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

Sold by 2 managers in 2026 Q3

  • 1 Owner
  • Max 0.5%
  • $114M
  • 1 reduce 1 exit

In 2026 Q3 Farallon Capital Management trimmed Tango Therapeutics, and Ron Baron sold out.

Who owns this now

Largest portfolio weights among holders, up to 0.5% (Farallon Capital Management). Not free-float ownership.

  1. Farallon Capital Management Reduce 0.49%

Who owns TNGX

Sorted by value, long equity only, as of 2026 Q3.

History
Farallon Capital Management 0.49%, was 1.8% Reduce −62.9% 4,550,688 $114M History
Ron Baron, BAMCO Inc. (Baron Capital) exited 2026 Q3 Last 2026 Q2 <0.01% Exit 0.00% 15,000 $469K History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TNGX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TNGX insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $7.4M sold by 3 insiders under 10b5-1 plans
  1. John B. Ketchum Director
    Planned sale
    $80K 3,333 shares at $24.08 13% of stake
    Traded Nov 17 Filed Nov 19
  2. Adam Crystal President, R&D
    Planned sale
    $125K 5,000 shares at $25.00 4.1% of stake
    Traded Nov 11 Filed Nov 13
  3. Adam Crystal President, R&D
    Planned sale
    $112K 5,000 shares at $22.42 4.1% of stake
    Traded Nov 2 Filed Nov 4
  4. Jessica Newcomb Principal Accounting Officer
    Planned sale
    $158K 7,031 shares at $22.42 12% of stake
    Traded Nov 2 Filed Nov 4
  5. Adam Crystal President, R&D
    Planned sale
    $661K 27,000 shares at $24.47 19% of stake
    Traded Oct 1 Filed Oct 5
  6. Jessica Newcomb Principal Accounting Officer
    Planned sale
    $199K 8,200 shares at $24.22 12% of stake
    Traded Sep 22 Filed Sep 24
  7. Adam Crystal President, R&D
    Planned sale
    $604K 27,000 shares at $22.37 19% of stake
    Traded Sep 1 Filed Sep 3
  8. Adam Crystal President, R&D
    Planned sale
    $736K 27,000 shares at $27.24 19% of stake
    Traded Aug 3 Filed Aug 5
  9. Adam Crystal President, R&D
    Planned sale
    $799K 27,000 shares at $29.59 19% of stake
    Traded Jul 1 Filed Jul 2
  10. Adam Crystal President, R&D
    Planned sale
    $618K 27,000 shares at $22.87 19% of stake
    Traded Jun 1 Filed Jun 3
  11. Adam Crystal President, R&D
    Planned sale
    $573K 27,000 shares at $21.23 19% of stake
    Traded May 1 Filed May 5
  12. Adam Crystal President, R&D
    Planned sale
    $962K 38,460 shares at $25.00 26% of stake
    Traded Apr 15 Filed Apr 16
  13. Adam Crystal President, R&D
    Planned sale
    $572K 27,000 shares at $21.20 19% of stake
    Traded Apr 1 Filed Apr 2
  14. Adam Crystal President, R&D
    Planned sale
    $241K 12,000 shares at $20.11 9.6% of stake
    Traded Mar 25 Filed Mar 27
  15. Adam Crystal President, R&D
    Planned sale
    $304K 20,251 shares at $15.00 15% of stake
    Traded Mar 5 Filed Mar 9

Also filed in the last 12 months, not counted as buying or selling: 12 stock grants, 11 option exercises, and 6 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
SCHEDULE 13G/A —
8-K 7.01,8.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
424B5
8-K 8.01,9.01
8-K/A 5.02,7.01,9.01
8-K 5.02
8-K 5.02,9.01
424B5
8-K 1.01,9.01
8-K 7.01,8.01,9.01
424B5
8-K 5.07
SCHEDULE 13G/A —

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $36.53M $42.07M $62.38M
Net income -$101.74M -$130.3M -$101.59M
Net margin * -278.5% -309.7% -162.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $346.54M $266.34M $353.76M
Total non-current assets * $56.03M $50.15M $44.93M
Total assets $402.57M $316.49M $398.69M
Total current liabilities $45.94M $38.17M $21.68M
Total non-current liabilities * $103.52M $78.8M $30.83M
Total equity $253.11M $199.52M $346.18M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$117.98M -$131.5M -$138.89M
Cash from investing $41.43M $86.13M -$40.86M
Cash from financing $82.41M $47.66M $222.5M
Net change in cash $5.85M $2.29M $42.75M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf